Atlas Trials

Basilea Pharmaceutica

58 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Basilea Pharmaceutica

RecordFirmDate
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects (NCT07500181)Basilea Pharmaceutica2026-03-04
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. (NCT06925321)Basilea Pharmaceutica2025-08-26
A Study of Fosmanogepix in Healthy Adult Chinese Subjects (NCT06961708)Basilea Pharmaceutica2025-04-14
A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin (NCT06808646)Basilea Pharmaceutica2025-01-17
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination (NCT06733675)Basilea Pharmaceutica2025-01-07
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (NCT05421858)Basilea Pharmaceutica2024-12-11
Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age (NCT06665555)Basilea Pharmaceutica2024-11-04
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age (NCT05856227)Basilea Pharmaceutica2023-08-06
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function. (NCT05582187)Basilea Pharmaceutica2022-10-31
Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function (NCT05488678)Basilea Pharmaceutica2022-10-12
Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants (NCT05527834)Basilea Pharmaceutica2022-09-13
A Bioequivalence Study of APX001 High-load and Low-load Tablets (NCT05491733)Basilea Pharmaceutica2021-03-02
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (NCT04604132)Basilea Pharmaceutica2020-10-06
VNRX-5024 Safety and PK in Healthy Adult Volunteers (NCT04314206)Basilea Pharmaceutica2020-07-27
VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers (NCT04243863)Basilea Pharmaceutica2020-01-20
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (NCT04240886)Basilea Pharmaceutica2020-01-04
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (NCT04148287)Basilea Pharmaceutica2019-12-13
Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects (NCT04098692)Basilea Pharmaceutica2019-08-08
Derazantinib and Atezolizumab in Patients With Urothelial Cancer (NCT04045613)Basilea Pharmaceutica2019-08-02
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia (NCT03604705)Basilea Pharmaceutica2018-10-03
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia (NCT03138733)Basilea Pharmaceutica2018-08-26
A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males (NCT04804059)Basilea Pharmaceutica2018-08-17
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (NCT03137173)Basilea Pharmaceutica2018-02-19
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia (NCT03333005)Basilea Pharmaceutica2017-11-27
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia (NCT03439124)Basilea Pharmaceutica2017-11-27
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (NCT03230318)Basilea Pharmaceutica2017-09-28

Track Basilea Pharmaceutica automatically

Every clearance here is in the API, with alerts when new ones post.